Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis

Prior treatment

• Respiratory infections within 3 months prior to enrollment (Day 0), including but not limited to: acute bacterial/viral pneumonia, acute bronchitis, Influenza, COVID-19 or acute exacerbation of chronic bronchitis.
• Positive urine pregnancy test, or breastfeeding women, or any women who are planning to become pregnant (current and within 3 months).
  • Prior/Concomitant Therapy
• ICS-based medication (including ICS, ICS/LABA, ICS/LABA/LAMA) use within 3 months prior to enrollment (Day 0).
  • ICS=inhaled corticosteroids; LABA=long-acting β2 agonists; LAMA=long-acting muscarinic antagonists.
  • Other Exclusions

Other illness

• Medical Conditions
• History of other chronic respiratory diseases other than asthma, including but not limited to tuberculosis, significant bronchiectasis, established interstitial lung disease, and lung cancer.
• History of serious comorbidities, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could:
  • Affect the safety of the patient throughout the study,
  • Confound the study results or impact the scientific validity of the data outcome,
  • Impede the patient's ability to complete the entire duration of study.

Other

• Patients are excluded from the study if any of the following criteria apply:
• Current smoker; or cessation from smoking less than 6 months; or cessation smoking for more than 6 months but smoked more than 10 packs/year.
• Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
• Current participation in another interventional clinical trial.

• Participants must meet all the following criteria and sign an informed consent form (ICF) to be eligible for the study.
• Patient must be aged 18-75 years old at the time of enrollment.
• Presented with asthmatic symptoms such as wheezing, shortness of breath, chest tightness and cough ≥2 months prior to enrollment (Day 0), with/without an established asthma diagnosis.